NR3C1 Antibody

What is NR3C1 and why is it an important research target?

NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1), commonly known as the Glucocorticoid Receptor (GR), is a critical transcription factor that binds to glucocorticoid response elements in promoters of glucocorticoid-responsive genes. The receptor is typically located in the cytoplasm but translocates to the nucleus upon ligand binding, where it regulates gene expression .

NR3C1 is expressed in almost every cell in the body and plays essential roles in:

• Development and metabolism regulation

• Immune response modulation

• Anti-inflammatory processes through up-regulation of anti-inflammatory proteins

• Pro-inflammatory protein repression through cytosolic mechanisms

• Chromatin remodeling

• Rapid mRNA degradation

Diseases associated with NR3C1 include Glucocorticoid Resistance (Generalized) and Conn's Syndrome, making it a valuable research target for understanding steroid hormone resistance mechanisms and developing therapeutic interventions .

What are the primary applications of NR3C1 antibodies in research settings?

NR3C1 antibodies serve multiple research applications with distinct methodological approaches:

For optimal results, researchers should use specialized protocols like the Foxp3/Transcription Factor Staining Buffer Set for flow cytometry applications, and appropriate antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0) for IHC .

How should researchers select the appropriate NR3C1 antibody for their specific experimental needs?

Selecting the optimal NR3C1 antibody requires consideration of multiple factors:

• Species reactivity: Ensure compatibility with your experimental model. Available antibodies show reactivity with human, mouse, and rat samples, with some cross-reactivity to other species like non-human primates, rabbit, sheep, Xenopus, and yeast .

• Antibody type:

  • Monoclonal antibodies (e.g., clones BuGR2, OTI7A11) offer high specificity and reproducibility

  • Polyclonal antibodies provide broader epitope recognition and potentially stronger signals

• Application compatibility: Verify validation data for your specific application. Some antibodies are optimized for particular applications (e.g., Western blot vs. IHC vs. ChIP) .

• Immunogen information: Consider the immunogen used to generate the antibody. For instance:

  • PB9342 targets unspecified regions with guaranteed reactivity to human, mouse, rat samples

  • MAB10144 targets human GR/NR3C1 (Val271-Lys777)

  • CF806207 targets amino acids 1-265 of human NR3C1

• Validation evidence: Review available validation data including Western blot images showing expected molecular weight (85-97 kDa), immunohistochemistry staining patterns, and knockout/knockdown controls .

For applications requiring precise subcellular localization (nuclear vs. cytoplasmic), select antibodies with demonstrated ability to detect both compartments, as NR3C1 translocates upon activation .

What are the optimal sample preparation protocols for detecting NR3C1 in different experimental contexts?

Sample preparation varies significantly based on application, with specific requirements for detecting NR3C1:

For Western Blot analysis:

• Use high salt/sonication protocol for nuclear extracts, as NR3C1 can be tightly chromatin-bound

• Add 0.05% Tween 20 to blocking and primary antibody incubation buffers to enhance detection

• Sample preparation protocol for cell lysates:

  • Rinse cells in ice-cold PBS

  • Scrape or trypsinize cells

  • Centrifuge at ~3000 x g for 2-3 minutes

  • Add lysis buffer

  • Sonicate for 10-15 seconds

  • Centrifuge at ~10,000 x g for 10 minutes

  • Collect supernatant avoiding lipid phase

For Immunohistochemistry:

• Heat-mediated antigen retrieval is essential, preferably using:

  • EDTA buffer (pH 8.0) for optimal epitope exposure

  • Alternatively, citrate buffer (pH 6.0)

• Block with 10% goat serum

• Incubate with primary antibody overnight at 4°C

• Use biotinylated secondary antibody (30 min at 37°C)

• Develop using Strepavidin-Biotin-Complex with DAB as chromogen

For Flow Cytometry:

• Use specialized buffers like Foxp3/Transcription Factor Staining Buffer Set

• Follow one-step protocol for intracellular (nuclear) proteins

• Optimal cell numbers range from 10^5 to 10^8 cells per test

How can researchers troubleshoot weak or non-specific NR3C1 antibody signals?

When encountering signal issues with NR3C1 antibodies, consider these methodological approaches to troubleshooting:

For weak signals:

• Antibody concentration: Increase primary antibody concentration within recommended ranges (e.g., 1:500 instead of 1:2000 for WB)

• Incubation conditions: Extend primary antibody incubation to overnight at 4°C

• Signal enhancement: For WB, add 0.05% Tween 20 to blocking and antibody buffers

• Protein extraction optimization: Use high salt/sonication protocol for nuclear extracts to release chromatin-bound NR3C1

• Antigen retrieval: For IHC, optimize heat-mediated antigen retrieval using EDTA buffer (pH 8.0)

• Detection system: Use more sensitive detection systems (e.g., SuperSignal West Femto for WB)

For non-specific signals:

• Antibody validation: Verify antibody specificity using positive controls (e.g., HeLa, HepG2 cells) and negative controls (knockout/knockdown samples)

• Blocking optimization: Increase blocking time or concentration (e.g., 5% non-fat milk/TBS for 1.5 hours)

• Wash stringency: Increase wash times and detergent concentration (e.g., TBS-0.1% Tween)

• Secondary antibody dilution: Optimize secondary antibody dilution (typically 1:5000)

• Cross-reactivity elimination: Pre-adsorb antibodies or use highly purified antibodies like Picoband® that guarantee minimal background

Western blot protein loading should be optimized at approximately 30 μg per lane, with molecular weight verification at 86-100 kDa depending on post-translational modifications .

What controls should be included when using NR3C1 antibodies for functional studies?

Robust experimental design with NR3C1 antibodies requires comprehensive controls:

Essential positive controls:

• Cell lines with known NR3C1 expression:

  • HeLa human cervical epithelial carcinoma

  • HepG2 human liver cancer cells

  • A549 human lung carcinoma

  • U-87 MG human glioblastoma cells

• Tissue samples with verified expression:

  • Human placenta tissue

  • Rat/mouse brain and liver tissues

Negative controls:

• NR3C1 knockout or knockdown samples (siRNA, CRISPR)

• Primary antibody omission

• Isotype controls for monoclonal antibodies

• Pre-immune serum for polyclonal antibodies

Specificity controls:

• Peptide competition assays using the immunizing peptide

• Cross-validation with alternative antibody clones

• Detection of expected molecular weight (86-97 kDa)

• Confirmation of expected subcellular localization patterns:

  • Cytoplasmic in unstimulated conditions

  • Nuclear after glucocorticoid treatment

Treatment controls:

• Dexamethasone treatment to induce nuclear translocation

• RU486 (mifepristone) as a glucocorticoid receptor antagonist

• Time-course experiments to monitor dynamic responses

For ChIP experiments, include input controls, IgG controls, and positive controls targeting known NR3C1 binding sites in glucocorticoid-responsive genes .

How can researchers accurately interpret changes in NR3C1 localization in response to stimuli?

NR3C1 exhibits dynamic subcellular localization that requires careful experimental design and interpretation:

Methodological approach to localization studies:

• Use immunofluorescence with high-resolution microscopy to track subcellular distribution

• Combine with nuclear/cytoplasmic fractionation and Western blotting

• Implement time-course experiments following stimulation (15min, 30min, 1h, 3h, 24h)

• Quantify nuclear/cytoplasmic ratio using digital image analysis

Key considerations for accurate interpretation:

• Baseline localization: In unstimulated cells, NR3C1 predominantly resides in the cytoplasm in complexes with heat shock proteins and immunophilins

• Translocation kinetics: After ligand binding, expect progressive nuclear accumulation within 15-30 minutes

• Cell type variations: Different cell types may show variable translocation efficiency and kinetics

• Ligand specificity: Different glucocorticoids (dexamethasone, cortisol, prednisolone) may induce varying degrees of translocation

• Simultaneous protein level changes: Monitor total NR3C1 levels, as some treatments may affect both localization and expression

Potential data misinterpretation pitfalls:

• Fixation artifacts that disrupt normal localization patterns

• Antibody epitope masking during protein-protein interactions

• Overexpression systems showing atypical localization patterns

• Confounding effects of cell cycle stage on nuclear permeability

For rigorous analysis, complement immunostaining with biochemical fractionation and quantitative microscopy techniques such as high-content imaging .

What mechanisms underlie NR3C1 mutations and their impact on steroid resistance in clinical contexts?

Research on NR3C1 mutations reveals complex mechanisms underlying steroid resistance:

Molecular mechanisms of resistance:

• Deletions affecting gene dosage: Heterozygous NR3C1 deletions (found in ~4% of T-ALL patients) reduce receptor expression and correlate with steroid resistance

• Truncating mutations: Premature frameshifts (e.g., E116fs) or nonsense mutations (e.g., G371X) produce non-functional receptors lacking DNA binding and ligand-binding domains

• Missense mutations: Amino acid substitutions (e.g., G568W, N130D, R386L) may disrupt:

  • Ligand binding affinity

  • Nuclear translocation

  • DNA binding capacity

  • Transcriptional co-regulator recruitment

• Expression regulation: Mechanisms decreasing NR3C1 expression contribute to resistance, though baseline mRNA levels don't necessarily correlate with steroid response

Clinical implications from research findings:

• Approximately 7% of T-ALL patients harbor NR3C1 inactivating events at diagnosis

• NR3C1 aberrations correlate significantly with prednisolone resistance (p=0.0078)

• Mutations found at diagnosis differ functionally from those selected during therapy

• NR3C1 mutations may synergize with other genetic aberrations to confer resistance

Laboratory models for studying resistance mechanisms:

• REH cells with engineered NR3C1 mutations provide controlled experimental systems

• Primary patient samples with naturally occurring mutations offer clinical relevance

• Functional assays measuring steroid-induced apoptosis and transcriptional responses

Research suggests that natural steroid hormones may exert selection pressure on (pre)leukemic cells even before diagnosis, explaining the presence of resistance-conferring mutations at initial presentation .

How can ChIP assays with NR3C1 antibodies be optimized to identify glucocorticoid receptor binding sites?

Chromatin Immunoprecipitation (ChIP) with NR3C1 antibodies requires specific optimization strategies:

Protocol optimization:

• Crosslinking conditions: Optimize formaldehyde concentration (0.75-1%) and time (8-15 minutes) to preserve protein-DNA interactions without overfixation

• Sonication parameters: Adjust sonication to yield DNA fragments of 200-500bp for optimal resolution

• Antibody selection: Use ChIP-validated antibodies with proven specificity for NR3C1

• Antibody amounts: Typical range of 2-5 μg per ChIP reaction, requiring empirical optimization

• Washing stringency: Balance between reducing background and maintaining specific signals

• Elution conditions: Optimize to maximize recovery of bound DNA

Experimental design considerations:

• Treatment conditions:

  • Include dexamethasone treatment (typical 100nM for 1-4 hours)

  • Include time course experiments to capture transient vs. stable binding events

• Controls:

  • Input controls (10% pre-immunoprecipitation chromatin)

  • IgG negative controls

  • Positive controls targeting known GR binding sites

  • Non-treated controls to establish baseline binding

Data analysis approaches:

• ChIP-qPCR: For targeted analysis of specific loci

• ChIP-seq: For genome-wide binding site identification

• CUT&RUN or CUT&Tag: For higher resolution with less material

• Sequential ChIP: To identify co-occupancy with other factors

Recent methodological advances show that specialized buffers and commercial kits (e.g., ChIP-IT High Sensitivity) can improve results with transcription factors like NR3C1 that may have transient interactions with chromatin .

How do different NR3C1 isoforms affect antibody selection and experimental interpretation?

NR3C1 exists in multiple isoforms that impact antibody selection and data interpretation:

Major NR3C1 isoforms and their characteristics:

• Alternative splicing generates multiple isoforms with varying functions

• GRα (94-97 kDa) is the predominant active isoform

• GRβ lacks the ligand-binding domain and can act as a dominant negative regulator

• Additional isoforms (GRγ, GR-A, GR-P) have tissue-specific distributions and functions

Antibody selection strategies:

• Epitope location: Select antibodies targeting:

  • N-terminal domains (amino acids 1-265) for detecting most isoforms

  • C-terminal regions for isoform-specific detection

  • Junction-specific antibodies for exclusive isoform recognition

• Validation evidence: Verify antibody capability to distinguish between isoforms through Western blot analysis showing multiple bands with expected molecular weights

• Application-specific considerations: Different applications may require different isoform targeting strategies:

  • Functional studies may require isoform-specific antibodies

  • Expression studies may benefit from pan-isoform antibodies

Data interpretation considerations:

• Western blots may show multiple bands representing different isoforms (86-97 kDa range)

• Post-translational modifications (phosphorylation, ubiquitination) can affect apparent molecular weight

• Tissue and cell-specific isoform expression patterns must be considered

• Treatment effects may differentially affect isoform expression ratios

When studying NR3C1 isoform-specific functions, researchers should combine antibody-based approaches with molecular techniques like RT-PCR to confirm isoform identity .

What are the best methods for investigating NR3C1 protein-protein interactions using antibody-based approaches?

Investigating NR3C1 protein interactions requires specialized methodological approaches:

Co-Immunoprecipitation (Co-IP) optimization:

• Lysate preparation: Use gentle lysis buffers containing:

  • 150-300mM NaCl

  • 0.5-1% NP-40 or Triton X-100

  • Protease and phosphatase inhibitors

  • 5-10% glycerol to stabilize interactions

• Antibody selection: Choose antibodies that:

  • Don't interfere with interaction domains

  • Function efficiently in immunoprecipitation

  • Have been validated for Co-IP applications

• Technical considerations:

  • Pre-clear lysates with protein A/G beads

  • Use appropriate antibody amounts (2-5 μg per mg protein)

  • Include appropriate controls (IgG, input)

  • Consider crosslinking antibodies to beads to avoid heavy chain detection

Proximity Ligation Assay (PLA) for in situ interactions:

• Use two primary antibodies from different species targeting NR3C1 and its potential interactor

• Apply species-specific secondary antibodies conjugated with oligonucleotides

• Ligation and amplification generate fluorescent spots where proteins are in close proximity (<40nm)

• Quantify interaction signals in different cellular compartments

Reciprocal IP validation strategy:

• Perform IP with anti-NR3C1 antibody, blot for interacting partner

• Perform reverse IP with antibody against interacting partner, blot for NR3C1

• Confirm interactions under different conditions (with/without hormone stimulation)

Advanced approaches:

• RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins) for unbiased interaction screening

• ChIP-reChIP to identify co-occupancy on chromatin

• BioID or APEX proximity labeling to capture transient interactions

How can researchers accurately quantify changes in NR3C1 expression levels across different experimental conditions?

Accurate quantification of NR3C1 expression changes requires multi-faceted methodological approaches:

Western blot quantification:

• Sample preparation standardization:

  • Extract proteins using consistent protocols

  • Determine protein concentration with precision

  • Load equal amounts (20-30 μg) per lane

• Technical considerations:

  • Include loading controls (β-actin, GAPDH, or nuclear-specific controls like Lamin B)

  • Use validated antibodies with linear detection range (e.g., 0.1-0.5 μg/ml for Western blot)

  • Implement digital densitometry with background subtraction

  • Normalize to multiple loading controls for reliability

qRT-PCR for mRNA quantification:

• Primer design: Use primers spanning exon-exon junctions

• Reference gene selection: Use multiple stable reference genes

• Calculation method: Apply ΔΔCt method with efficiency correction

• Validation: Correlate with protein expression when possible

Flow cytometry for single-cell analysis:

• Use validated antibodies (e.g., BuGR2 clone)

• Apply specialized fixation/permeabilization (Foxp3/Transcription Factor buffer)

• Analyze median fluorescence intensity (MFI) for quantification

• Include calibration beads for standardization across experiments

Research insights on expression quantification:

• Baseline NR3C1 mRNA levels do not necessarily correlate with steroid response in patient samples

• NR3C1 expression upregulation following steroid exposure may be more predictive of response than baseline levels

• In controlled cell line experiments, there is stronger correlation between NR3C1 levels and steroid response compared to primary patient samples

• Expression changes should be measured at both protein and mRNA levels due to potential post-transcriptional regulation

Research demonstrates that NR3C1-deleted T-ALL patients have significantly lower NR3C1 expression compared to wild-type patients (p=0.0017) , highlighting the importance of accurate quantification methods in clinical research contexts.

How do epigenetic modifications impact NR3C1 function, and what methods can detect these relationships?

Recent research reveals complex epigenetic regulation of NR3C1 with important methodological implications:

Key epigenetic mechanisms affecting NR3C1:

• DNA methylation of the NR3C1 promoter regions

• Histone modifications (H3K4me3, H3K27ac, H3K9me3) affecting chromatin accessibility

• Chromatin remodeling influencing NR3C1 binding site accessibility

• Non-coding RNAs regulating NR3C1 expression post-transcriptionally

Methodological approaches to study epigenetic regulation:

• Bisulfite sequencing for DNA methylation analysis of NR3C1 promoter

• ChIP-seq for histone modification landscapes at NR3C1 locus and target genes

• ATAC-seq to measure chromatin accessibility at GR binding sites

• 3C/4C/Hi-C to investigate chromatin conformation affecting NR3C1 regulation

• CUT&Tag for efficient profiling of histone modifications with low cell numbers

Integrative analysis approaches:

• Combine ChIP-seq for NR3C1 with histone modification mapping

• Correlate DNA methylation with expression changes

• Integrate chromatin accessibility data with transcriptional outcomes

• Apply multi-omics approaches to build comprehensive regulatory models

Research shows that NR3C1 itself participates in chromatin remodeling, creating a complex feedback system where the receptor both responds to and modifies the epigenetic landscape. This understanding has implications for interpreting antibody-based studies of NR3C1, as epitope accessibility may be affected by local chromatin environment .

What are the latest methodological advances in studying NR3C1 signaling networks using antibody-based proteomics?

Cutting-edge proteomics approaches are transforming NR3C1 research:

Advanced proteomics methodologies:

• Proximity-dependent biotinylation (BioID/TurboID):

  • Fuse NR3C1 to biotin ligase

  • Identify proteins in proximity through streptavidin pulldown

  • Map dynamic interactomes under different hormonal conditions

• Tandem Mass Tag (TMT) quantitative proteomics:

  • Compare NR3C1 interaction partners across conditions

  • Identify post-translational modifications

  • Measure signaling dynamics with temporal resolution

• Reverse Phase Protein Arrays (RPPA):

  • Analyze hundreds of samples simultaneously

  • Quantify NR3C1 pathway components

  • Validate antibodies across large sample sets

• Single-cell proteomics:

  • Mass cytometry (CyTOF) with metal-conjugated antibodies

  • Microfluidic-based single-cell Western blotting

  • Spatial proteomics with multiplexed antibody imaging

Antibody-based pathway analysis:

• Phospho-specific antibodies to track GR activation and downstream signaling

• Multiplex immunoassays to simultaneously measure multiple pathway components

• Antibody arrays for broad pathway activation profiling

• Proximity ligation assays for visualizing protein interactions in situ

Emerging applications:

• Patient-derived organoids for personalized medicine approaches

• CRISPR screens combined with antibody-based readouts

• Systems biology integration of proteomics with transcriptomics and metabolomics

These approaches provide comprehensive insights into how NR3C1 functions within complex signaling networks, enabling researchers to move beyond isolated protein studies toward understanding system-level behaviors in health and disease .

How can researchers effectively use NR3C1 antibodies to study glucocorticoid resistance mechanisms in patient samples?

Studying glucocorticoid resistance in patient samples requires specialized methodological strategies:

Clinical sample-specific considerations:

• Sample preservation:

  • Flash freezing for protein/RNA analysis

  • FFPE processing with optimal fixation for IHC

  • Viable cell preservation for functional assays

• Patient stratification:

  • Group by steroid response (resistant vs. sensitive)

  • Categorize by disease subtype

  • Classify by treatment stage (diagnostic, relapsed, refractory)

• Antibody selection for clinical samples:

  • Validated for human tissues/cells

  • Compatible with available sample types (FFPE, frozen)

  • Sensitive enough for limited material

Methodological approaches for resistance mechanism investigation:

• Mutation and deletion screening:

  • Combine sequencing with loss of heterozygosity (LOH) analysis

  • Use antibodies that can detect truncated forms or isoforms

  • Correlate genomic findings with protein expression

• Expression analysis:

  • Measure NR3C1 expression by IHC in tissue sections

  • Quantify using digital pathology for standardization

  • Compare with in vitro steroid response

• Functional assays:

  • Ex vivo steroid sensitivity testing

  • Measurement of NR3C1 nuclear translocation

  • Assessment of target gene induction

Research insights:

• T-ALL patients with NR3C1 aberrations show significantly inferior in vitro steroid response compared to wild-type patients (p=0.0078)

• Relative basal NR3C1 mRNA expression alone does not predict steroid responsiveness in primary patient samples

• The ability to upregulate steroid response genes (including NR3C1 itself and pro-apoptotic BIM) following steroid exposure appears more predictive of response

• Approximately 7% of diagnostic T-ALL patient samples harbor NR3C1 inactivating events that influence leukemic response to steroid treatment

These findings suggest that comprehensive analysis combining genetic, expression, and functional approaches provides the most complete picture of resistance mechanisms in clinical contexts.